Joint (NASDAQ: JYNT) and RPX (NASDAQ:RPXC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.
Volatility & Risk
Joint has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, RPX has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
This table compares Joint and RPX’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Joint||$25.16 million||3.76||-$3.27 million||($0.25)||-27.82|
|RPX||$330.46 million||1.68||-$79.14 million||N/A||N/A|
Joint has higher earnings, but lower revenue than RPX.
This table compares Joint and RPX’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
RPX pays an annual dividend of $0.10 per share and has a dividend yield of 0.9%. Joint does not pay a dividend.
This is a summary of current ratings and recommmendations for Joint and RPX, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Joint currently has a consensus target price of $6.82, indicating a potential downside of 1.99%. RPX has a consensus target price of $14.33, indicating a potential upside of 29.13%. Given RPX’s higher possible upside, analysts clearly believe RPX is more favorable than Joint.
Institutional and Insider Ownership
49.6% of Joint shares are held by institutional investors. Comparatively, 89.8% of RPX shares are held by institutional investors. 6.1% of Joint shares are held by company insiders. Comparatively, 3.5% of RPX shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
RPX beats Joint on 8 of the 14 factors compared between the two stocks.
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. The Company has approximately 310 franchised, company-owned, or managed clinics in operation in over 30 states. In addition to its approximately 310 operating clinics, the Company has granted franchises either directly or through its regional developers for an additional over 170 clinics. The Company offers a range of membership and wellness packages. Each patient’s records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
RPX Corporation is engaged in providing an alternative to litigation through its patent risk management services. The Company helps companies reduce patent litigation risk and corporate legal expense through two primary service offerings: patent risk management services and discovery services. It operates through two segments: patent risk management and discovery services. Its patent risk management segment generates its revenues from membership subscriptions, premiums earned from insurance policies, and management fees for marketing, underwriting, and claim management. Its discovery services segment generates its revenues from fees generated for data collection, hosting and processing, project management, and document review services. The Company serves clients in a range of industries, including consumer electronics, personal computers, e-commerce, financial services, software, media content and distribution, mobile communications and handsets, networking and semiconductors.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.